Investors hammered Heron Therapeutics on 27 January, with shares tumbling as low as 19.2% in morning trading, after the company revealed it was forced to delay by at least three months its resubmission to the FDA of the firm’s new drug application (NDA) for its experimental chemotherapy-induced nausea and vomiting (CINV) drug Sustol (APF530).
Shares of Heron closed at $11.50, a loss of $1, or 8%.






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
